HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
The Week

At ASCO, Merck makes case for a 'cornerstone' cancer drug

Study results accrued so far are giving Merck greater conviction that the therapy, licensed from a China-based biotech, was worth placing into a sprawling Phase 3 program.

By BioPharma Dive · May 29, 2026 · via BioPharma Dive
At ASCO, Merck makes case for a 'cornerstone' cancer drug

Image: BioPharma Dive

This is an aggregated industry headline. Read the full story at BioPharma Dive →

Tags
theweekformat:headlineheadlineBioPharma Dive
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
MannKind seeks long-awaited sales boost with inhaled insulin approval for kids
The WeekFiercePharma ↗
MannKind seeks long-awaited sales boost with inhaled insulin approval for kids
With a pediatric approval in hand for Afrezza, MannKind may finally have the boost it needs to make an impact …
May 30, 2026
Legend scientific founder returns to ASCO with new ambition for high-yield, non-gene-editing CAR-T platform
The WeekFierceBiotech ↗
Legend scientific founder returns to ASCO with new ambition for high-yield, non-gene-editing CAR-T platform
Nine years after wowing the audience at the American Society of Clinical Oncology annual meeting with a CAR-T …
May 30, 2026
Leadership Change, Clinical Setbacks, and an ADC Milestone in a Busy FDA Week
The WeekBriefing
Leadership Change, Clinical Setbacks, and an ADC Milestone in a Busy FDA Week
Allogene’s founding CEO steps down, Agios halts development of tebapivat, AbbVie gains approval for Decnupaz, …
May 30, 2026